$CERO News

CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment

CERo Therapeutics Hldgs Q1 EPS $(0.20) Beats $(1.00) Estimate

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

CERo Therapeutics Announces Trading on OTCQB Market

CERo Therapeutics Hldgs Q3 EPS $(9.10) Misses $(2.94) Estimate

CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

CERo Therapeutics Holdings Initiated Second Cohort Of Phase 1 CER-1236 Clinical Trial Focused On Patients With Acute Myeloid Leukemia

CERo Therapeutics Holdings Initiated Second Cohort Of Phase 1 CER-1236 Clinical Trial Focused On Patients With Acute Myeloid Leukemia

CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

CERo Therapeutics To Present Preclinical Data On Its Lead Compound, CER-1236, Showing CER-1236 Exhibits Sustained Effector Function, Robust Cytokine Responses, And Resistance To Exhaustion Compared To Standard CD3/CD28 Stimulation

Maxim Group Downgrades CERo Therapeutics Hldgs to Hold